Zymeworks (ZYME) Q2 2024 earnings summary

Executive summary

• Achieved key regulatory milestones for zanidatamab, including FDA Priority Review for 2L BTC (PDUFA date Nov 29, 2024), EMA validation, and BLA acceptance in China, triggering an $8M milestone payment from BeiGene.

• Advanced early-stage pipeline with FDA IND clearances for ZW171 and ZW191, with first-in-human studies planned for 2H 2024; IND filings for ZW220 and ZW251 expected in 2025.

• Discontinued clinical development of zanidatamab zovodotin (ZW49) to focus resources on early-stage programs; recorded a $17.3M impairment charge.

• Announced $60M share repurchase program, with $30M to be executed in H2 2024; appointment of Leone Patterson as EVP, CBO, and CFO effective September 1, 2024.

• Strategic partnerships with Jazz and BeiGene provide global development, commercialization opportunities, and significant milestone and royalty revenue potential.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $395.9M as of June 30, 2024, supporting a projected runway into 2H 2027.

• Revenue for the six months ended June 30, 2024, was $29.3M, down from $42.6M in 2023; Q2 2024 revenue was $19.2M, up 174% year-over-year.

• Net loss for the six months ended June 30, 2024, was $69.3M ($0.91 per share), improved from $75.5M in 2023.

• Operating expenses decreased year-over-year, with R&D at $61.2M and G&A at $31.5M for the first half of 2024.

• $8M milestone payment received from BeiGene for BLA acceptance in China.

Outlook and guidance

• Cash runway expected into 2H 2027, assuming receipt of anticipated milestone payments.

• Top-line data from pivotal HERIZON-GEA-01 trial expected in 2Q 2025; IND filings for ZW220 and ZW251 planned for 2025.

• Five novel therapeutics expected to enter the clinic by 2026, with potential to nominate two candidates annually from 2027 onward.